Periorbital edema secondary to imatinib mesylate

Collin M. McClelland, George J. Harocopos, Philip L. Custer

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia and for advanced gastrointestinal stromal tumors (GISTs). Edema-related side effects are relatively common in imatinib therapy with the periocular skin representing one of the most common sites for localized edema. While the adverse effect of periorbital edema with imatinib is well documented in the oncology literature, there is limited reference to this common reaction in the ophthalmology literature. We report two patients with upper eyelid edema associated with imatinib therapy who required surgical intervention to ameliorate significant visual field obstruction. We highlight the details of each case including the histo pathologic findings of excised redundant skin followed by a thorough review of the literature on imatinib related periorbital edema.

Original languageEnglish
Pages (from-to)427-431
Number of pages5
JournalClinical Ophthalmology
Issue number1
StatePublished - 2010


  • Edema
  • Gleevec
  • Imatinib mesylate
  • Periorbital edema
  • Tyrosine kinase inhibitor


Dive into the research topics of 'Periorbital edema secondary to imatinib mesylate'. Together they form a unique fingerprint.

Cite this